{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T17:15:48Z","timestamp":1790874948066,"version":"4.1.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T00:00:00Z","timestamp":1743724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T00:00:00Z","timestamp":1743724800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"DOI":"10.1186\/s12876-025-03802-5","type":"journal-article","created":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T03:14:05Z","timestamp":1743822845000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Prolonged time interval from neoadjuvant immunotherapy combined with chemotherapy to surgery is related to unimproved pathological response and poor survival prognosis for esophageal squamous cell carcinoma"],"prefix":"10.1186","volume":"25","author":[{"given":"Guanzhi","family":"Ye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaojian","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongming","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guojun","family":"Geng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,4]]},"reference":[{"key":"3802_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Ca-Cancer J Clin. 2024;74:229\u201363.","journal-title":"Ca-Cancer J Clin"},{"key":"3802_CR2","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1053\/j.gastro.2022.05.054","volume":"163","author":"E Morgan","year":"2022","unstructured":"Morgan E, Soerjomataram I, Rumgay H, Coleman HG, Thrift AP, Vignat J, et al. The global landscape of esophageal squamous cell carcinoma and esophageal adenocarcinoma incidence and mortality in 2020 and projections to 2040: new estimates from globocan 2020. Gastroenterology. 2022;163:649\u201358.","journal-title":"Gastroenterology"},{"key":"3802_CR3","doi-asserted-by":"publisher","first-page":"393","DOI":"10.6004\/jnccn.2023.0019","volume":"21","author":"JA Ajani","year":"2023","unstructured":"Ajani JA, D\u2019Amico TA, Bentrem DJ, Cooke D, Corvera C, Das P, et al. Esophageal and esophagogastric junction cancers, version 2.2023, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Ne. 2023;21:393\u2013422.","journal-title":"J Natl Compr Canc Ne"},{"key":"3802_CR4","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003497","volume":"10","author":"W Yang","year":"2022","unstructured":"Yang W, Xing X, Yeung SJ, Wang S, Chen W, Bao Y, et al. Neoadjuvant programmed cell death 1 blockade combined with chemotherapy for resectable esophageal squamous cell carcinoma. J Immunother Cancer. 2022;10: e003497.","journal-title":"J Immunother Cancer"},{"key":"3802_CR5","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.39778","volume":"5","author":"F Ge","year":"2022","unstructured":"Ge F, Huo Z, Cai X, Hu Q, Chen W, Lin G, et al. Evaluation of clinical and safety outcomes of neoadjuvant immunotherapy combined with chemotherapy for patients with resectable esophageal cancer: a systematic review and meta-analysis. Jama Netw Open. 2022;5: e2239778.","journal-title":"Jama Netw Open"},{"key":"3802_CR6","doi-asserted-by":"publisher","first-page":"155","DOI":"10.3892\/ol.2023.13741","volume":"25","author":"J Liu","year":"2023","unstructured":"Liu J, Zeng X, Zhou X, Xu Y, Ding Z, Hu Y, et al. Longer interval between neoadjuvant chemoradiotherapy and surgery is associated with improved pathological response, but does not accurately estimate survival in patients with resectable esophageal cancer. Oncol Lett. 2023;25:155.","journal-title":"Oncol Lett"},{"key":"3802_CR7","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.athoracsur.2016.02.058","volume":"102","author":"A Lee","year":"2016","unstructured":"Lee A, Wong AT, Schwartz D, Weiner JP, Osborn VW, Schreiber D. Is there a benefit to prolonging the interval between neoadjuvant chemoradiation and esophagectomy in esophageal cancer? Ann Thorac Surg. 2016;102:433\u20138.","journal-title":"Ann Thorac Surg"},{"key":"3802_CR8","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/j.annonc.2023.08.010","volume":"34","author":"K Nilsson","year":"2023","unstructured":"Nilsson K, Klevebro F, Sunde B, Rouvelas I, Lindblad M, Szabo E, et al. Oncological outcomes of standard versus prolonged time to surgery after neoadjuvant chemoradiotherapy for oesophageal cancer in the multicentre, randomised, controlled NeoRes II trial. Ann Oncol. 2023;34:1015\u201324.","journal-title":"Ann Oncol"},{"key":"3802_CR9","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.jtcvs.2023.08.056","volume":"167","author":"Y Yang","year":"2024","unstructured":"Yang Y, Liu J, Liu Z, Zhu L, Chen H, Yu B, et al. Two-year outcomes of clinical N2\u20133 esophageal squamous cell carcinoma after neoadjuvant chemotherapy and immunotherapy from the phase 2 NICE study. J Thorac Cardiov Sur. 2024;167:838\u201347.","journal-title":"J Thorac Cardiov Sur"},{"key":"3802_CR10","doi-asserted-by":"crossref","unstructured":"Liu J, Yang Y, Liu Z, Fu X, Cai X, Li H, et al. Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma. J Immunother Cancer. 2022;10(3):e004291.","DOI":"10.1136\/jitc-2021-004291"},{"key":"3802_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijsu.2022.106680","volume":"103","author":"X Yan","year":"2022","unstructured":"Yan X, Duan H, Ni Y, Zhou Y, Wang X, Qi H, et al. Tislelizumab combined with chemotherapy as neoadjuvant therapy for surgically resectable esophageal cancer: a prospective, single-arm, phase II study (TD-NICE). Int J Surg. 2022;103: 106680.","journal-title":"Int J Surg"},{"key":"3802_CR12","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","volume":"62","author":"LH Schwartz","year":"2016","unstructured":"Schwartz LH, Litiere S, de Vries E, Ford R, Gwyther S, Mandrekar S, et al. Recist 1.1-update and clarification: from the recist committee. Eur J Cancer. 2016;62:132\u20137.","journal-title":"Eur J Cancer"},{"key":"3802_CR13","doi-asserted-by":"publisher","first-page":"doz078","DOI":"10.1093\/dote\/doz078","volume":"33","author":"F Klevebro","year":"2020","unstructured":"Klevebro F, Nilsson K, Lindblad M, Ekman S, Johansson J, Lundell L, et al. Association between time interval from neoadjuvant chemoradiotherapy to surgery and complete histological tumor response in esophageal and gastroesophageal junction cancer: a national cohort study. Dis Esophagus. 2020;33:doz078.","journal-title":"Dis Esophagus"},{"key":"3802_CR14","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/j.athoracsur.2013.12.026","volume":"97","author":"W Tessier","year":"2014","unstructured":"Tessier W, Gronnier C, Messager M, Hec F, Mirabel X, Robb WB, et al. Does timing of surgical procedure after neoadjuvant chemoradiation affect outcomes in esophageal cancer? Ann Thorac Surg. 2014;97:1181\u20139.","journal-title":"Ann Thorac Surg"},{"key":"3802_CR15","doi-asserted-by":"publisher","first-page":"4245","DOI":"10.1245\/s10434-013-3139-7","volume":"20","author":"CH Chiu","year":"2013","unstructured":"Chiu CH, Chao YK, Chang HK, Tseng CK, Chan SC, Liu YH, et al. Interval between neoadjuvant chemoradiotherapy and surgery for esophageal squamous cell carcinoma: does delayed surgery impact outcome? Ann Surg Oncol. 2013;20:4245\u201351.","journal-title":"Ann Surg Oncol"},{"key":"3802_CR16","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.athoracsur.2014.08.033","volume":"99","author":"T Shaikh","year":"2015","unstructured":"Shaikh T, Ruth K, Scott WJ, Burtness BA, Cohen SJ, Konski AA, et al. Increased time from neoadjuvant chemoradiation to surgery is associated with higher pathologic complete response rates in esophageal cancer. Ann Thorac Surg. 2015;99:270\u20136.","journal-title":"Ann Thorac Surg"},{"key":"3802_CR17","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2016.2743","volume":"151","author":"KR Haisley","year":"2016","unstructured":"Haisley KR, Laird AE, Nabavizadeh N, Gatter KM, Holland JM, Vaccaro GM, et al. Association of intervals between neoadjuvant chemoradiation and surgical resection with pathologic complete response and survival in patients with esophageal cancer. Jama Surg. 2016;151: e162743.","journal-title":"Jama Surg"},{"key":"3802_CR18","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1007\/s11605-023-05851-1","volume":"27","author":"T Maramara","year":"2023","unstructured":"Maramara T, Shridhar R, Blinn P, Huston J, Meredith K. Timing after neoadjuvant therapy predicts mortality in patients undergoing esophagectomy: a propensity score-matched analysis. J Gastrointest Surg. 2023;27:2342\u201351.","journal-title":"J Gastrointest Surg"},{"key":"3802_CR19","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1007\/s00262-024-03787-2","volume":"73","author":"G Yang","year":"2024","unstructured":"Yang G, Hong Y, Zhang X, Zeng C, Tan L, Zhang X. Impact of the interval between neoadjuvant immunotherapy and surgery on prognosis in esophageal squamous cell carcinoma (ESCC): a real-world study. Cancer Immunol Immun. 2024;73:202.","journal-title":"Cancer Immunol Immun"},{"key":"3802_CR20","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s00432-024-05696-4","volume":"150","author":"J Liu","year":"2024","unstructured":"Liu J, Zhu L, Huang X, Lu Z, Wang Y, Yang Y, et al. Does the time interval from neoadjuvant camrelizumab combined with chemotherapy to surgery affect outcomes for locally advanced esophageal squamous cell carcinoma? J Cancer Res Clin. 2024;150:161.","journal-title":"J Cancer Res Clin"},{"key":"3802_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/dote\/dox116","volume":"31","author":"H Tie","year":"2018","unstructured":"Tie H, He F, Shen J, Zhang B, Ye M, Chen B, et al. Prolonged interval between neoadjuvant chemoradiotherapy and esophagectomy does not benefit the outcome in esophageal cancer: a systematic review and meta-analysis. Dis Esophagus. 2018;31:1\u20139.","journal-title":"Dis Esophagus"},{"key":"3802_CR22","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1097\/SLA.0b013e3181fc7f86","volume":"252","author":"A Ruol","year":"2010","unstructured":"Ruol A, Rizzetto C, Castoro C, Cagol M, Alfieri R, Zanchettin G, et al. Interval between neoadjuvant chemoradiotherapy and surgery for squamous cell carcinoma of the thoracic esophagus: does delayed surgery have an impact on outcome? Ann Surg. 2010;252:788\u201396.","journal-title":"Ann Surg"},{"key":"3802_CR23","doi-asserted-by":"publisher","unstructured":"Overtoom H, Eyck BM, van der Wilk BJ, Noordman BJ, van der Sluis PC, Wijnhoven B, et al. Prolonged time to surgery in patients with residual disease after neoadjuvant chemoradiotherapy for esophageal cancer. Ann Surg. 2024. https:\/\/doi.org\/10.1097\/SLA.0000000000006488. Epub ahead of print.","DOI":"10.1097\/SLA.0000000000006488"},{"key":"3802_CR24","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1097\/SLA.0000000000006476","volume":"280","author":"J Wang","year":"2024","unstructured":"Wang J, de Jongh C, Wu Z, de Groot EM, Alexandre C, Markar SR, et al. Impact of preoperative time intervals for neoadjuvant chemoradiotherapy on short-term postoperative outcomes of esophageal cancer surgery: a population-based study using the dutch upper gastrointestinal cancer audit (DUCA) data. Ann Surg. 2024;280:808\u201316.","journal-title":"Ann Surg"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-03802-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-025-03802-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-03802-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T03:14:10Z","timestamp":1743822850000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-025-03802-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,4]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3802"],"URL":"https:\/\/doi.org\/10.1186\/s12876-025-03802-5","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,4]]},"assertion":[{"value":"10 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study complied with the Declaration of Helsinki and was approved by the Ethics Committee of the First Affiliated Hospital of Xiamen University on 26 February 2024 (protocol number: XMYY-2024KYSB090). Due to the retrospective character of this analysis and the approval by the Ethics Committee of the First Affiliated Hospital of Xiamen University, the need for informed consent to participate was unnecessary.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"223"}}